Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

Published:2024-08 Issue: Volume:187 Page:128-138
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Valabrega Giorgio,Pothuri Bhavana,Oaknin Ana,Graybill Whitney S.,Sánchez Ana Beatriz,McCormick Colleen,Baurain Jean-François,Tinker Anna V.,Denys Hannelore,O’Cearbhaill Roisin E.,Hietanen Sakari,Moore Richard G.,Knudsen Anja Ør,de La Motte Rouge Thibault,Heitz Florian,Levy Tally,York Whitney,Gupta Divya,Monk Bradley J.,González-Martín Antonio

Funder

GSK

Publisher

Elsevier BV

Reference42 articles.

1. Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis;Zhang;BMC Cancer,2019

2. Ovarian cancer in the world: epidemiology and risk factors;Momenimovahed;Int. J. Women's Health,2019

3. SEER cancer Statistics Review, 1975–2017;Howlader,2020

4. Age as a prognostic factor in ovarian carcinoma: the Gynecologic Oncology Group experience;Thigpen;Cancer,1993

5. Treatment and trials: ovarian cancer in older women;Freyer;ASCO Education Book,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP